3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
46
Carcinoma, Hepatocellular
13
Osteosarcoma
8
Neoplasms
8
Sarcoma
7
Prostatic Neoplasms
7
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Sarcoma, Ewing
6
Neuroendocrine Tumors
6
Kidney Neoplasms
6
Clear-cell metastatic renal cell carcinoma
6
Carcinoma, Non-Small-Cell Lung
6
Thyroid Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Medullary
4
Carcinoma
4
Brain Neoplasms
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Ovarian Neoplasms
3
Melanoma
3
Endometrial Neoplasms
3
Adrenocortical Carcinoma
3
Wilms Tumor
2
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Interventions
belzutifan
4
Everolimus
2
spartalizumab
1
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Nivolumab
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
cabozantinib
×
1 year
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled